Dr. Albert DeNittis, MD

Lankenau Medical Center

Expert in Cancer
Expert in Lung Cancer
59 reported clinical trials
120 drugs studied
3 years of experience

About Albert DeNittis, MD


  • Received MD from Sidney Kimmel Medical College (formerly Jefferson Medical College) in 1986.
  • Completed Residency in Internal Medicine at Lankenau Medical Center in 1989.
  • Finished Fellowship in Hematology/Oncology at Fox Chase Cancer Center in 1992.


  • Affiliated with Lankenau Medical Center and Main Line Health.
  • Practices as a hematologist and oncologist.

Area of expertise

Global Leader
Albert DeNittis, MD has run 29 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage III
2Lung Cancer
Global Leader
Albert DeNittis, MD has run 17 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage III

Affiliated Hospitals

Image of trial facility.
Lankenau Medical Center
Image of trial facility.
Paoli Memorial Hospital

Clinical Trials Albert DeNittis, MD is currently running

Image of trial facility.

Fulvestrant + Binimetinib

for Breast Cancer

This ComboMATCH phase II trial compares the usual treatment alone (fulvestrant) to using binimetinib plus the usual treatment in patients with hormone receptor positive breast cancer that has spread from where it first started to other places in the body (metastatic) and has an NF1 genetic change. Fulvestrant is a hormonal therapy that binds to estrogen receptors in tumor cells, resulting in estrogen receptor destruction and decreased estrogen binding, which may inhibit the growth of estrogen-sensitive tumor cells. Binimetinib is a targeted therapy that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. The addition of binimetinib to fulvestrant in breast cancers with an NF1 genetic change could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to fulvestrant alone.
Recruiting1 award Phase 219 criteria
Image of trial facility.

Symptom Monitoring

for Young Women on Hormone Therapy

This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines.
Recruiting1 award N/A13 criteria

More about Albert DeNittis, MD

Clinical Trial Related3 years of experience running clinical trials · Led 59 trials as a Principal Investigator · 34 Active Clinical Trials
Treatments Albert DeNittis, MD has experience with
  • Paclitaxel
  • Carboplatin
  • Pembrolizumab
  • Atezolizumab
  • Olaparib
  • Docetaxel

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Albert DeNittis, MD specialize in?
Albert DeNittis, MD focuses on Cancer and Lung Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Albert DeNittis, MD currently recruiting for clinical trials?
Yes, Albert DeNittis, MD is currently recruiting for 33 clinical trials in Wynnewood Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Albert DeNittis, MD has studied deeply?
Yes, Albert DeNittis, MD has studied treatments such as Paclitaxel, Carboplatin, Pembrolizumab.
What is the best way to schedule an appointment with Albert DeNittis, MD?
Apply for one of the trials that Albert DeNittis, MD is conducting.
What is the office address of Albert DeNittis, MD?
The office of Albert DeNittis, MD is located at: Lankenau Medical Center, Wynnewood, Pennsylvania 19096 United States. This is the address for their practice at the Lankenau Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.